World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
70
Citations
13394
World Ranking
2456
National Ranking
1175

Alan L. Epstein publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Alan L. Epstein sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 281 publications — 59th percentile

59% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Alan L. Epstein D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Alan L. Epstein sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 70 D-Index — 52nd percentile

52% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Alan L. Epstein is affiliated with the University of Southern California in the United States. Their research spans several interconnected fields with a primary focus on Medicine, Biochemistry, Genetics and Molecular Biology, and Immunology and Microbiology.

Epstein's subfields of study include Immunology, Oncology, Molecular Biology, Cancer Research, and Radiology, Nuclear Medicine and Imaging. The core topics they have explored involve Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immune Cell Function and Interaction, Immune cells in cancer, Monoclonal and Polyclonal Antibodies Research, T-cell and B-cell Immunology, and RNA Interference and Gene Delivery.

Frequent co-authors collaborating with Epstein include Leslie A. Khawli, Peisheng Hu, Vyshnavi Pachipulusu, Aida Kouhi, and Long Zheng.

Epstein has published multiple articles across various respected venues. Their recent papers include:

  • Principles of N-Linked Glycosylation Variations of IgG-Based Therapeutics: Pharmacokinetic and Functional Considerations, 2020, published in Antibodies
  • Brain Disposition of Antibody-Based Therapeutics: Dogma, Approaches and Perspectives, 2021, in International Journal of Molecular Sciences
  • Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes, 2022, in Molecular Therapy
  • Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppression, 2022, in Blood
  • Molecular profiling reveals a hypoxia signature in breast implant-associated anaplastic large cell lymphoma, 2020, in Haematologica

Publications by Epstein frequently appear in venues such as The American Journal of Gastroenterology, Neuro-Oncology, The Journal of Immunology, Journal of Neurosurgery, and Cancer Research.

Best Publications

  • Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells

    Melissa G. Lechner;Daniel J. Liebertz;Alan L. Epstein

  • Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases.

    Garry S. Brody;Dennis Deapen;Clive R. Taylor;Lauren Pinter-Brown

  • Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy.

    Melissa G. Lechner;Saman S. Karimi;Keegan Barry-Holson;Trevor E. Angell

  • Functional characterization of human Cd33+ And Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines

    Melissa G Lechner;Carolina Megiel;Sarah M Russell;Brigid Bingham

  • Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines

    Alan L. Epstein;Ronald Levy;Hun Kim;Werner Henle

  • Detection of necrotic malignant tissue and associated therapy

    Alan L. Epstein;Clive R. Taylor

  • Genetically Engineered Cell-Derived Nanoparticles for Targeted Breast Cancer Immunotherapy.

    Xiaojing Shi;Qinqin Cheng;Tianling Hou;Menglu Han

  • Nuclear domain 10 (ND10) associated proteins are also present in nuclear bodies and redistribute to hundreds of nuclear sites after stress.

    Gerd G. Maul;Eunsil Yu;Alexander M. Ishov;Alan L. Epstein

  • Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential.

    Alan L. Epstein;Robert J. Marder;Jane N. Winter;Efstathois Stathopoulos

  • A novel method for the detection of necrotic lesions in human cancers.

    Alan L. Epstein;Feng-Ming Chen;Clive R. Taylor

  • A method for simultaneous nuclear immunofluorescence and DNA content quantitation using monoclonal antibodies and flow cytometry

    Charles V. Clevenger;Kenneth D. Bauer;Alan L. Epstein

  • Biomarkers Provide Clues to Early Events in the Pathogenesis of Breast Implant-Associated Anaplastic Large Cell Lymphoma.

    Marshall E. Kadin;Anand Deva;Haiying Xu;John Morgan

  • Biology of the human malignant lymphomas. I. Establishment in continuous cell culture and heterotransplantation of diffuse histiocytic lymphomas.

    Alan L. Epstein;Henry S. Kaplan

  • Treatment of B cell malignancies with 131I LYM‐1 monoclonal antibodies

    S. J. Denardo;Gerald L Denardo;L. F. O'Grady;E. Hu

  • Enhanced Tumor Uptake of Macromolecules Induced by a Novel Vasoactive Interleukin 2 Immunoconjugate

    Brian LeBerthon;Leslie A. Khawli;Mian Alauddin;Gordon K. Miller

  • Comparative serum stability of radiochelates for antibody radiopharmaceuticals.

    William C. Cole;Sally J. DeNardo;Claude F. Meares;Michael J. McCall

  • Immunohistochemical analysis of human lymphomas with monoclonal antibodies to B cell and Ia antigens reactive in paraffin sections.

    Marder Rj;Variakojis D;Silver J;Epstein Al

  • MHC Class I Loss Is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer That Is Reversed by Interferon and Selumetinib Treatment In Vitro

    Trevor E. Angell;Melissa G. Lechner;Julie K. Jang;Jonathan S. LoPresti

  • Pivotal Study of Iodine-131–Labeled Chimeric Tumor Necrosis Treatment Radioimmunotherapy in Patients With Advanced Lung Cancer

    Shaoliang Chen;Like Yu;Changying Jiang;Yan Zhao

  • Modulation of Treg cells/T effector function by GITR signaling is context–dependent

    Amal Ephrem;Alan L. Epstein;Geoffrey L. Stephens;Angela M. Thornton

  • Pretreatment with a Monoclonal Antibody/Interleukin-2 Fusion Protein Directed against DNA Enhances the Delivery of Therapeutic Molecules to Solid Tumors

    Jason L. Hornick;Leslie A. Khawli;Peisheng Hu;Jahangir Sharifi

  • Survival Signals and Targets for Therapy in Breast Implant–Associated ALK− Anaplastic Large Cell Lymphoma

    Melissa G. Lechner;Carolina Megiel;Connor H. Church;Trevor E. Angell

Frequent Co-Authors

Leslie A. Khawli
Leslie A. Khawli University of Southern California
Clive R. Taylor
Clive R. Taylor University of Southern California
Jason L. Hornick
Jason L. Hornick Brigham and Women's Hospital
Charles V. Clevenger
Charles V. Clevenger Virginia Commonwealth University
Bellur S. Prabhakar
Bellur S. Prabhakar University of Illinois at Chicago
Henry S. Kaplan
Henry S. Kaplan Stanford University
L. Jeffrey Medeiros
L. Jeffrey Medeiros The University of Texas MD Anderson Cancer Center
Walter J. Storkus
Walter J. Storkus University of Pittsburgh
Susan Groshen
Susan Groshen University of Southern California
Honggang Cui
Honggang Cui Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology can open doors to various healthcare careers, many of which can be enhanced through specialized nursing education. For those interested in advancing their clinical skills, transitioning from a Family Nurse Practitioner to an Acute Care Nurse Practitioner can be a strategic move. You can find detailed guidance on how to make this shift by exploring fnp to acnp pathways.

For individuals aiming to enter the nursing field quickly, there are multiple options available to accelerate your education. Choosing an accelerated fnp program online allows you to fast-track your Family Nurse Practitioner career without sacrificing quality.

If you’re new to nursing altogether, don’t worry—there are excellent online nursing programs for non nurses that provide foundational knowledge and prepare you for advanced immunology-related roles.

Additionally, some prospective students look for less competitive programs to begin their nursing journey. The easiest accelerated nursing programs offer accessible entry points while maintaining standards that prepare you for diverse healthcare opportunities.

Best Scientists Citing Alan L. Epstein

Trending Scientists

Recently Published Articles